糖尿病患者白内障手术中玻璃体内注射地塞米松:一项更新的文献综述
本综述综合现有证据,探讨糖尿病患者接受白内障手术(尤其超声乳化)时,玻璃体内注射地塞米松治疗糖尿病黄斑水肿的时机与疗效,以确定改善结局的最佳时机。研究提示及时注射可显著减轻炎症并促进视力恢复,术前注射可能有效抑制手术创伤引发的炎症反应,但各研究剂量与时机差异较大,需标准化方案。
要点
- 及时玻璃体内注射地塞米松可显著减轻糖尿病黄斑水肿患者白内障术后的炎症并促进视力恢复。
- 术前注射可能有效抑制手术创伤引发的炎症反应,术中及术后给药有助于恢复期持续抗炎。
- 地塞米松在预防黄斑囊样水肿方面优于非甾体抗炎药等其他抗炎治疗,但研究间剂量与时机差异大。
核心结论
- 玻璃体内注射地塞米松是糖尿病患者白内障手术中管理糖尿病黄斑水肿的有价值干预,最佳时机对最大化治疗获益至关重要。
- 术前注射似乎特别有益于降低术后炎症并发症风险。
研究设计与样本
- 系统综述,检索关键数据库纳入同行评议研究、临床试验和荟萃分析。
- 纳入研究涉及白内障手术(尤其超声乳化)背景下糖尿病黄斑水肿患者术前、术中及术后接受地塞米松注射。
- 研究选择基于与时机、视力结局和炎症控制的相关性,重点关注比较疗效。
主要发现
- 研究提示及时地塞米松注射可显著减轻炎症并促进糖尿病黄斑水肿患者白内障术后的视力恢复。
- 术前注射可能有效抑制手术创伤引发的炎症反应,可能保护视网膜完整性。
- 术中及术后给药有助于恢复期持续抗炎效果。
- 比较研究强调地塞米松优于非甾体抗炎药等其他抗炎治疗,尤其在预防黄斑囊样水肿方面。
- 各研究间剂量和时机存在相当大差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 各研究间剂量和时机存在相当大差异,凸显需要标准化治疗方案。
- 进一步研究应侧重于制定时机和剂量的综合指南,以标准化治疗并改善这一高危人群的患者结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This literature review synthetizes current evidence on the timing and efficacy of dexamethasone intravitreal injections for diabetic macular edema in patients undergoing cataract surgery, particularly phacoemulsification, to determine the optimal timing for improved outcome. METHODS: A systematic review of the literature was conducted across key databases to identify peer-reviewed studies, clinical trials, and meta-analyses addressing dexamethasone injections administered pre-, intra-, and postoperatively for diabetic macular edema in the context of cataract surgery. Studies were selected based on relevance to timing, visual outcomes, and inflammation control, with a focus on comparative efficacy. RESULTS: The findings suggest that timely dexamethasone injections can substantially reduce inflammation and enhance visual recovery for patients with diabetic macular edema undergoing cataract surgery. Studies indicate that preoperative injections may effectively dampen the inflammatory response triggered by surgical trauma, potentially preserving retinal integrity, whereas intraoperative and postoperative administrations contribute to sustained anti-inflammatory effects during the recovery phase. Comparative studies also highlight dexamethasone's advantages over other anti-inflammatory treatments, such as NSAIDs, particularly in preventing cystoid macular edema. Notably, there was considerable variation in dosage and timing across studies, underscoring the need for standardized treatment protocols. CONCLUSION: Dexamethasone intravitreal injections offer a valuable intervention for managing diabetic macular edema in diabetic patients undergoing cataract surgery, with optimal timing playing a crucial role in maximizing therapeutic benefits. Preoperative injections appear to be particularly beneficial in reducing the risk of postoperative inflammatory complications. Further research should focus on developing comprehensive guidelines for timing and dosage to standardize treatment and improve patient outcomes in this high-risk population.
引用
- Meduri A, De Luca L, Oliverio GW, et al. DEXAMETHASONE INTRAVITREAL INJECTION IN DIABETIC PATIENTS UNDERGOING CATARACT SURGERY: An Updated Literature Review. Retina. 2025. PMID: 39787414. doi:10.1097/IAE.0000000000004381
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。